Loading...

Tashkin Donald

TitleDirector
InstitutionUniversity of California Los Angeles
DepartmentPulmonary Function Laboratories
Address32-176 CHS
Campus - 169017
Phone(310) 825-3163
vCardDownload vCard
    Other Positions
    TitleProfessor

    TitleCo-Director

    TitleCo-Director


    Collapse Research 
    Collapse Research Activities and Funding
    SPIROMICS Clinical Center
    NIH/NHLBI 268200900015C-4-0-1Feb 2, 2009 - Dec 31, 2015
    Role: Principal Investigator
    SPIRIOMICS Clinical Center
    NIH/NHLBI 268200900015C-4-0-2Feb 2, 2009 - Dec 31, 2015
    Role: Principal Investigator
    SPIROMICS Clinical Center
    NIH/NHLBI 268200900015C-1-0-1Feb 1, 2009 - Jan 31, 2016
    Role: Principal Investigator
    MOCSLID-CCC
    NIH/NHLBI R01HL089758Sep 18, 2008 - Jul 31, 2014
    Role: Principal Investigator
    Distal Lung Inflammation Effect on Asthma Exacerbations
    NIH/NHLBI R01HL080343Sep 15, 2005 - Jul 31, 2010
    Role: Principal Investigator
    Scleroderma Lung Study
    NIH/NHLBI U01HL060587Aug 10, 1999 - Jun 30, 2006
    Role: Principal Investigator
    PATHOPHYSIOLOGIC CONSEQUENCES OF SMOKED SUBSTANCE ABUSE
    NIH/NIDA R13DA012627Apr 15, 1999 - Mar 31, 2000
    Role: Principal Investigator
    LUNG HEALTH STUDY--LONG TERM FOLLOW UP
    NIH/NHLBI U10HL059293Feb 1, 1998 - Jan 31, 2003
    Role: Principal Investigator
    CLINICAL TRIAL OF INHALED STEROIDS IN COPD
    NIH/NHLBI U01HL050270Sep 4, 1993 - Dec 31, 1999
    Role: Principal Investigator
    Cocaine Smoking Effects on Lung Immunity &Host Defense
    NIH/NIDA R01DA008254Jun 1, 1993 - Aug 31, 2007
    Role: Co-Principal Investigator
    EARLY INTERVENTION/CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    NIH/NHLBI N01HR046022Sep 30, 1984 - Sep 30, 1999
    Role: Principal Investigator
    Pulmonary and Immunologic Effects of Marijuana Use on HIV and Viral Immunity
    NIH/NIDA R01DA003018Jul 1, 1982 - Apr 30, 2012
    Role: Co-Principal Investigator
    PULMONARY EFFECTS OF HABITUAL USE OF MARIJUANA
    NIH/NIDA R37DA003018Jul 1, 1982 - Sep 29, 2006
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Tashkin D. To Withdraw or Not to Withdraw Inhaled Corticosteroids from Triple Therapy in COPD. Am J Respir Crit Care Med. 2018 Jun 19. PMID: 29916719.
      View in: PubMed
    2. Tashkin D, Gross NJ. Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018; 13:1873-1888. PMID: 29928118.
      View in: PubMed
    3. Khanna D, Tashkin D, Denton CP, Lubell MW, Vazquez-Mateo C, Wax S. Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). 2018 Jun 08. PMID: 29893938.
      View in: PubMed
    4. Tashkin D. Marijuana and Lung Disease. Chest. 2018 May 17. PMID: 29778658.
      View in: PubMed
    5. Namas R, Tashkin D, Furst DE, Wilhalme H, Tseng CH, Roth MD, Kafaja S, Volkmann E, Clements PJ, Khanna D. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. Arthritis Care Res (Hoboken). 2018 Mar; 70(3):439-444. PMID: 28544580.
      View in: PubMed
    6. Morris MA, Jacobson SR, Kinney GL, Tashkin D, Woodruff PG, Hoffman EA, Kanner RE, Cooper CB, Drummond MB, Barr RG, Oelsner EC, Make BJ, Han MK, Hansel NN, O'Neal WK, Bowler RP. Marijuana Use Associations with Pulmonary Symptoms and Function in Tobacco Smokers Enrolled in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). Chronic Obstr Pulm Dis. 2018 Jan 24; 5(1):46-56. PMID: 29629404.
      View in: PubMed
    7. Tashkin D, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018; 13:335-349. PMID: 29403271.
      View in: PubMed
    8. Kiertscher SM, Gangalum PR, Ibrahim G, Tashkin D, Roth MD. A Prospective Study of Humoral and Cellular Immune Responses to Hepatitis B Vaccination in Habitual Marijuana Smokers. J Neuroimmune Pharmacol. 2018 Jun; 13(2):219-229. PMID: 29340893.
      View in: PubMed
    9. Bhatt SP, Kim YI, Harrington KF, Hokanson JE, Lutz SM, Cho MH, DeMeo DL, Wells JM, Make BJ, Rennard SI, Washko GR, Foreman MG, Tashkin D, Wise RA, Dransfield MT, Bailey WC. Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. Thorax. 2018 May; 73(5):414-421. PMID: 29326298.
      View in: PubMed
    10. Polosa R, Cibella F, Caponnetto P, Maglia M, Prosperini U, Russo C, Tashkin D. Health impact of E-cigarettes: a prospective 3.5-year study of regular daily users who have never smoked. Sci Rep. 2017 Nov 17; 7(1):13825. PMID: 29150612.
      View in: PubMed
    11. Kafaja S, Clements PJ, Wilhalme H, Tseng CH, Furst DE, Kim GH, Goldin J, Volkmann ER, Roth MD, Tashkin D, Khanna D. Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). Am J Respir Crit Care Med. 2017 Nov 03. PMID: 29099620.
      View in: PubMed
    12. Anderson WH, Ha JW, Couper DJ, O'Neal WK, Barr RG, Bleecker ER, Carretta EE, Cooper CB, Doerschuk CM, Drummond MB, Han MK, Hansel NN, Kim V, Kleerup EC, Martinez FJ, Rennard SI, Tashkin D, Woodruff PG, Paine R, Curtis JL, Kanner RE. Variability in objective and subjective measures affects baseline values in studies of patients with COPD. PLoS One. 2017; 12(9):e0184606. PMID: 28934249.
      View in: PubMed
    13. Ferguson GT, Tashkin D, Skärby T, Jorup C, Sandin K, Greenwood M, Pemberton K, Trudo F. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. Respir Med. 2017 Nov; 132:31-41. PMID: 29229103.
      View in: PubMed
    14. Khanna D, Seibold J, Goldin J, Tashkin D, Furst DE, Wells A. Interstitial lung disease points to consider for clinical trials in systemic sclerosis. Rheumatology (Oxford). 2017 09 01; 56(suppl_5):v27-v32. PMID: 28992174.
      View in: PubMed
    15. Tashkin D, Taube C. Triple Therapy for Chronic Obstructive Pulmonary Disease Management. Are Our Expectations Fulfilled? Am J Respir Crit Care Med. 2017 08 15; 196(4):402-404. PMID: 28809512.
      View in: PubMed
    16. Tashkin D, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C. Corrigendum to "A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD" [Respir. Med. 120 November 2016 16-24]. Respir Med. 2017 08; 129:164. PMID: 28732826.
      View in: PubMed
    17. Han MK, Quibrera PM, Carretta EE, Barr RG, Bleecker ER, Bowler RP, Cooper CB, Comellas A, Couper DJ, Curtis JL, Criner G, Dransfield MT, Hansel NN, Hoffman EA, Kanner RE, Krishnan JA, Martinez CH, Pirozzi CB, O'Neal WK, Rennard S, Tashkin D, Wedzicha JA, Woodruff P, Paine R, Martinez FJ. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017 08; 5(8):619-626. PMID: 28668356.
      View in: PubMed
    18. Volkmann ER, Tashkin D, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, Kim G, Goldin J, Clements PJ, Furst DE, Elashoff RM. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol. 2017 07; 69(7):1451-1460. PMID: 28376288.
      View in: PubMed
    19. Martinez CH, Murray S, Barr RG, Bleecker E, Bowler RP, Christenson SA, Comellas AP, Cooper CB, Couper D, Criner GJ, Curtis JL, Dransfield MT, Hansel NN, Hoffman EA, Kanner RE, Kleerup E, Krishnan JA, Lazarus SC, Leidy NK, O'Neal W, Martinez FJ, Paine R, Rennard SI, Tashkin D, Woodruff PG, Han MK. Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. Ann Am Thorac Soc. 2017 May; 14(5):636-642. PMID: 28459622.
      View in: PubMed
    20. Halpin DMG, Decramer M, Celli BR, Mueller A, Metzdorf N, Tashkin D. Effect of a single exacerbation on decline in lung function in COPD. Respir Med. 2017 07; 128:85-91. PMID: 28610675.
      View in: PubMed
    21. Li X, Obeidat M, Zhou G, Leung JM, Tashkin D, Wise R, Connett J, Joubert P, Bossé Y, van den Berge M, Brandsma CA, Nickle DC, Hao K, Paré PD, Sin DD. Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease. EBioMedicine. 2017 May; 19:139-145. PMID: 28461224.
      View in: PubMed
    22. Hanania NA, Tashkin D, Kerwin EM, Donohue JF, Denenberg M, O'Donnell DE, Quinn D, Siddiqui S, Orevillo C, Maes A, Reisner C. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017 05; 126:105-115. PMID: 28427541.
      View in: PubMed
    23. Desai M, Oppenheimer J, Tashkin D. Asthma-chronic obstructive pulmonary disease overlap syndrome: What we know and what we need to find out. Ann Allergy Asthma Immunol. 2017 Mar; 118(3):241-245. PMID: 28284529.
      View in: PubMed
    24. Meyers TJ, Chang SC, Chang PY, Morgenstern H, Tashkin D, Rao JY, Cozen W, Mack TM, Zhang ZF. Case-control study of cumulative cigarette tar exposure and lung and upper aerodigestive tract cancers. Int J Cancer. 2017 05 01; 140(9):2040-2050. PMID: 28164274.
      View in: PubMed
    25. Volkmann ER, Tashkin D, Roth MD, Clements PJ, Khanna D, Furst DE, Mayes M, Charles J, Tseng CH, Elashoff RM, Assassi S. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Res Ther. 2016 Dec 30; 18(1):305. PMID: 28038680.
      View in: PubMed
    26. Tashkin D, Volkmann ER, Tseng CH, Roth MD, Khanna D, Furst DE, Clements PJ, Theodore A, Kafaja S, Kim GH, Goldin J, Ariolla E, Elashoff RM. Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II. Chest. 2017 Apr; 151(4):813-820. PMID: 28012804.
      View in: PubMed
    27. Tashkin D, Kim HJ, Zeidler M, Kleerup E, Goldin J. Evaluating small-airways disease in asthmatic patients: The utility of quantitative computed tomography. J Allergy Clin Immunol. 2017 Jan; 139(1):49-51.e2. PMID: 27884601.
      View in: PubMed
    28. Wise RA, Acevedo RA, Anzueto AR, Hanania NA, Martinez FJ, Ohar JA, Tashkin D. Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus. Chronic Obstr Pulm Dis. 2016 Nov 15; 4(1):7-20. PMID: 28848907.
      View in: PubMed
    29. Volkmann ER, Tashkin D. Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies. Ann Am Thorac Soc. 2016 Nov; 13(11):2045-2056. PMID: 27560196.
      View in: PubMed
    30. Miles FL, Chang SC, Morgenstern H, Tashkin D, Rao JY, Cozen W, Mack T, Lu QY, Zhang ZF. Erratum to: Association of sugary beverages with survival among patients with cancers of the upper aerodigestive tract. Cancer Causes Control. 2016 Nov; 27(11):1301. PMID: 27757776.
      View in: PubMed
    31. Tashkin D. A review of nebulized drug delivery in COPD. Int J Chron Obstruct Pulmon Dis. 2016; 11:2585-2596. PMID: 27799757.
      View in: PubMed
    32. Tashkin D, Bateman ED, Jones P, Zubek VB, Metzdorf N, Liu D, Leonard T, Clerisme-Beaty E, Wise RA. Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses. Respir Med. 2016 11; 120:91-100. PMID: 27817821.
      View in: PubMed
    33. Tashkin D, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. Respir Med. 2016 11; 120:16-24. PMID: 27817811.
      View in: PubMed
    34. Miles FL, Chang SC, Morgenstern H, Tashkin D, Rao JY, Cozen W, Mack T, Lu QY, Zhang ZF. Association of sugary beverages with survival among patients with cancers of the upper aerodigestive tract. Cancer Causes Control. 2016 11; 27(11):1293-1300. PMID: 27539643.
      View in: PubMed
    35. Zafari Z, Sin DD, Postma DS, Löfdahl CG, Vonk J, Bryan S, Lam S, Tammemagi CM, Khakban R, Man SF, Tashkin D, Wise RA, Connett JE, McManus B, Ng R, Hollander Z, Sadatsafavi M. Individualized prediction of lung-function decline in chronic obstructive pulmonary disease. CMAJ. 2016 Oct 04; 188(14):1004-1011. PMID: 27486205.
      View in: PubMed
    36. Tashkin D, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 09; 4(9):708-719. PMID: 27469583.
      View in: PubMed
    37. Kerstjens HA, Moroni-Zentgraf P, Tashkin D, Dahl R, Paggiaro P, Vandewalker M, Schmidt H, Engel M, Bateman ED. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med. 2016 08; 117:198-206. PMID: 27492532.
      View in: PubMed
    38. Tkacova R, Dai DLY, Vonk JM, Leung JM, Hiemstra PS, van den Berge M, Kunz L, Hollander Z, Tashkin D, Wise R, Connett J, Ng R, McManus B, Paul Man SF, Postma DS, Sin DD. Airway hyperresponsiveness in chronic obstructive pulmonary disease: A marker of asthma-chronic obstructive pulmonary disease overlap syndrome? J Allergy Clin Immunol. 2016 Dec; 138(6):1571-1579.e10. PMID: 27345171.
      View in: PubMed
    39. Woodruff PG, Barr RG, Bleecker E, Christenson SA, Couper D, Curtis JL, Gouskova NA, Hansel NN, Hoffman EA, Kanner RE, Kleerup E, Lazarus SC, Martinez FJ, Paine R, Rennard S, Tashkin D, Han MK. Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. N Engl J Med. 2016 May 12; 374(19):1811-21. PMID: 27168432; PMCID: PMC4968204 [Available on 11/12/16].
    40. Celli BR, Decramer M, Liu D, Metzdorf N, Asijee GM, Tashkin D. Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial. Respir Res. 2016 05 04; 17(1):48. PMID: 27141828; PMCID: PMC4855862.
    41. Tashkin D, Moore GE, Trudo F, DePietro M, Chipps BE. Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients with Asthma. J Allergy Clin Immunol Pract. 2016 Jul-Aug; 4(4):705-12. PMID: 27039236.
      View in: PubMed
    42. Nelson MD, Rezk-Hanna M, Rader F, Mason OR, Tang X, Shidban S, Rosenberry R, Benowitz NL, Tashkin D, Elashoff RM, Lindner JR, Victor RG. Acute Effect of Hookah Smoking on the Human Coronary Microcirculation. Am J Cardiol. 2016 Jun 01; 117(11):1747-54. PMID: 27067622.
      View in: PubMed
    43. Putcha N, Barr RG, Han MK, Woodruff PG, Bleecker ER, Kanner RE, Martinez FJ, Smith BM, Tashkin D, Bowler RP, Eisner MD, Rennard SI, Wise RA, Hansel NN. Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort. Thorax. 2016 Mar 09. PMID: 26962015.
      View in: PubMed
    44. Miles FL, Chang SC, Morgenstern H, Tashkin D, Rao JY, Cozen W, Mack T, Lu QY, Zhang ZF. Associations of red and processed meat with survival among patients with cancers of the upper aerodigestive tract and lung. Nutr Res. 2016 06; 36(6):620-6. PMID: 27188908.
      View in: PubMed
    45. Kim HJ, Tashkin D, Gjertson DW, Brown MS, Kleerup E, Chong S, Belperio JA, Roth MD, Abtin F, Elashoff R, Tseng CH, Khanna D, Goldin JG. Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment. Ann Rheum Dis. 2016 Jul; 75(7):1367-71. PMID: 26757749.
      View in: PubMed
    46. Khanna D, Nagaraja V, Tseng CH, Abtin F, Suh R, Kim G, Wells A, Furst DE, Clements PJ, Roth MD, Tashkin D, Goldin J. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther. 2015 Dec 23; 17:372. PMID: 26704522; PMCID: PMC4718035.
    47. Douglas IS, Albertson TE, Folan P, Hanania NA, Tashkin D, Upson DJ, Leone FT. Implications of Marijuana Decriminalization on the Practice of Pulmonary, Critical Care, and Sleep Medicine. A Report of the American Thoracic Society Marijuana Workgroup. Ann Am Thorac Soc. 2015 Nov; 12(11):1700-10. PMID: 26540421.
      View in: PubMed
    48. Tashkin D. How beneficial is vaping cannabis to respiratory health compared to smoking? Addiction. 2015 Nov; 110(11):1706-7. PMID: 26471152.
      View in: PubMed
    49. Assassi S, Swindell WR, Wu M, Tan FD, Khanna D, Furst DE, Tashkin D, Jahan-Tigh RR, Mayes MD, Gudjonsson JE, Chang JT. Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis. Arthritis Rheumatol. 2015 Nov; 67(11):3016-26. PMID: 26238292.
      View in: PubMed
    50. Rennard SI, Sin DD, Tashkin D, Calverley PM, Radner F. The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia. Ann Am Thorac Soc. 2015 Oct; 12(10):1587-9. PMID: 26448356.
      View in: PubMed
    51. Tashkin D. The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015; 14(11):1759-72. PMID: 26401729.
      View in: PubMed
    52. Tashkin D. Smoking Cessation in Chronic Obstructive Pulmonary Disease. Semin Respir Crit Care Med. 2015 Aug; 36(4):491-507. PMID: 26238637.
      View in: PubMed
    53. Tashkin D. Advances in Prevention and Treatment of Chronic Obstructive Pulmonary Disease. Semin Respir Crit Care Med. 2015 Aug; 36(4):455-6. PMID: 26238633.
      View in: PubMed
    54. Tashkin D. The respiratory health benefits of quitting cannabis use. Eur Respir J. 2015 Jul; 46(1):1-4. PMID: 26130771.
      View in: PubMed
    55. Apperley S, Park HY, Holmes DT, Man SFP, Tashkin D, Wise RA, Connett JE, Sin DD. Serum Bilirubin and Disease Progression in Mild COPD. Chest. 2015 Jul; 148(1):169-175. PMID: 25539285; PMCID: PMC4493872.
    56. Volkmann ER, Tashkin D, Li N, Furst DE, Clements PJ, Elashoff RM. Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease. Rheumatology (Sunnyvale). 2015 Jun; 5(2). PMID: 28856069.
      View in: PubMed
    57. Halpin DMG, Tashkin D, Celli BR, Leimer I, Metzdorf N, Decramer M. Effect of Tiotropium on Outcomes in Patients With COPD, Categorized Using the New GOLD Grading System: Results of the UPLIFT® Randomized Controlled Trial. Chronic Obstr Pulm Dis. 2015 Jun 23; 2(3):236-251. PMID: 28848846.
      View in: PubMed
    58. Tashkin D, Leimer I, Metzdorf N, Decramer M. Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial. Respir Res. 2015 Jun 02; 16:65. PMID: 26031308; PMCID: PMC4475325.
    59. Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí AA, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin D, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. Eur Respir Rev. 2015 Jun; 24(136):159-72. PMID: 26028628.
      View in: PubMed
    60. Sze MA, Chen YW, Tam S, Tashkin D, Wise RA, Connett JE, Man SP, Sin DD. The relationship between Helicobacter pylori seropositivity and COPD. Thorax. 2015 Oct; 70(10):923-9. PMID: 26024688.
      View in: PubMed
    61. Anzueto A, Jenkins CR, Make BJ, Lindberg M, Calverley PM, Fagerås M, Postma DS, Rennard SI, Tashkin D. Efficacy of an inhaled corticosteroid/long-acting ß2-agonist combination in symptomatic COPD patients in GOLD groups B and D. Eur Respir J. 2015 Jul; 46(1):255-8. PMID: 26022947.
      View in: PubMed
    62. Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí A, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin D, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. Eur Respir J. 2015 Apr; 45(4):879-905. PMID: 25829431.
      View in: PubMed
    63. Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí A, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin D, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL. An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015 Apr 01; 191(7):e4-e27. PMID: 25830527.
      View in: PubMed
    64. Celli BR, Decramer M, Asijee GM, Kupas K, Tashkin D. Effects of Tiotropium on Exacerbations in Patients with COPD with Low or High Risk of Exacerbations: A Post-Hoc Analysis from the 4-Year UPLIFT® Trial. Chronic Obstr Pulm Dis. 2015 Mar 27; 2(2):122-130. PMID: 28848836.
      View in: PubMed
    65. Paulin LM, Diette GB, Blanc PD, Putcha N, Eisner MD, Kanner RE, Belli AJ, Christenson S, Tashkin D, Han M, Barr RG, Hansel NN. Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015 Mar 01; 191(5):557-65. PMID: 25562375; PMCID: PMC4384767.
    66. Tashkin D. Dual anti-inflammatory agents prevent COPD exacerbations. Lancet. 2015 Mar 07; 385(9971):832-4. PMID: 25684589.
      View in: PubMed
    67. Halpin DM, Dahl R, Hallmann C, Mueller A, Tashkin D. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis. 2015; 10:239-59. PMID: 25709423; PMCID: PMC4332287.
    68. Tashkin D. Does marijuana pose risks for chronic airflow obstruction? Ann Am Thorac Soc. 2015 Feb; 12(2):235-6. PMID: 25706487; PMCID: PMC4342838.
    69. Berger WE, Tashkin D. Flunisolide hydrofluoroalkane with integrated spacer for treating asthma: an updated review. Allergy Asthma Proc. 2015 Mar-Apr; 36(2):105-15. PMID: 25635610.
      View in: PubMed
    70. Huang YH, Zhang ZF, Tashkin D, Feng B, Straif K, Hashibe M. An epidemiologic review of marijuana and cancer: an update. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):15-31. PMID: 25587109; PMCID: PMC4302404.
    71. Tashkin D, Volkmann ER, Tseng CH, Kim HJ, Goldin J, Clements P, Furst D, Khanna D, Kleerup E, Roth MD, Elashoff R. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann Rheum Dis. 2016 Feb; 75(2):374-81. PMID: 25452309.
      View in: PubMed
    72. Donohue JF, Hanania NA, Make B, Miles MC, Mahler DA, Curry L, Tosiello R, Wheeler A, Tashkin D. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014 Dec; 146(6):1531-1542. PMID: 25451347; PMCID: PMC4251615.
    73. Tashkin D, Li N, Kleerup EC, Halpin D, Celli B, Decramer M, Elashoff R. Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD. Respir Res. 2014 Aug 31; 15:102. PMID: 25175805; PMCID: PMC4244051.
    74. Yang Y, Burke RV, Jeon CY, Chang SC, Chang PY, Morgenstern H, Tashkin D, Mao J, Cozen W, Mack TM, Rao J, Zhang ZF. Polymorphisms of peroxisome proliferator-activated receptors and survival of lung cancer and upper aero-digestive tract cancers. Lung Cancer. 2014 Sep; 85(3):449-56. PMID: 25043640.
      View in: PubMed
    75. Tashkin D. Increasing cannabis use: what we still need to know about its effects on the lung. Respirology. 2014 Jul; 19(5):619-20. PMID: 24862082.
      View in: PubMed
    76. Maspero J, Cherrez I, Doherty DE, Tashkin D, Kuna P, Kuo WL, Gates D, Nolte H, Chylack LT. Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma. Respir Med. 2014 Sep; 108(9):1355-62. PMID: 25044280.
      View in: PubMed
    77. Polosa R, Campagna D, Tashkin D. Subacute bronchial toxicity induced by an electronic cigarette: take home message. Thorax. 2014 Jun; 69(6):588. PMID: 24827822.
      View in: PubMed
    78. Streja L, Crespi CM, Bastani R, Wong GC, Jones CA, Bernert JT, Tashkin D, Hammond SK, Berman BA. Can a minimal intervention reduce secondhand smoke exposure among children with asthma from low income minority families? Results of a randomized trial. J Immigr Minor Health. 2014 Apr; 16(2):256-64. PMID: 22945813; PMCID: PMC3534823.
    79. Tashkin D, Chipps BE, Trudo F, Zangrilli JG. Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses. J Asthma. 2014 Aug; 51(6):603-9. PMID: 24524222; PMCID: PMC4162502.
    80. Park HY, Churg A, Wright JL, Li Y, Tam S, Man SF, Tashkin D, Wise RA, Connett JE, Sin DD. Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013 Dec 15; 188(12):1413-9. PMID: 24245748; PMCID: PMC3917377.
    81. Yang T, Chang PY, Park SL, Bastani D, Chang SC, Morgenstern H, Tashkin D, Mao JT, Papp JC, Rao JY, Cozen W, Mack TM, Greenland S, Zhang ZF. Tobacco smoking, NBS1 polymorphisms, and survival in lung and upper aerodigestive tract cancers with semi-Bayes adjustment for hazard ratio variation. Cancer Causes Control. 2014 Jan; 25(1):11-23. PMID: 24166361; PMCID: PMC3889468.
    82. Putcha N, Drummond MB, Connett JE, Scanlon PD, Tashkin D, Hansel NN, Wise RA. Chronic productive cough is associated with death in smokers with early COPD. COPD. 2014 Aug; 11(4):451-8. PMID: 24127996.
      View in: PubMed
    83. Tashkin D. Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin Pharmacother. 2014 Jan; 15(1):85-96. PMID: 24032576.
      View in: PubMed
    84. Boiselle PM, Crapo JD, Han MK, Lynch DA, Tashkin D. Expert opinion: how can quantitative CT benefit patients with COPD and idiopathic interstitial pneumonias? J Thorac Imaging. 2013 Sep; 28(5):263. PMID: 23934143.
      View in: PubMed
    85. Tashkin D, Li N, Halpin D, Kleerup E, Decramer M, Celli B, Elashoff R. Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. Respir Med. 2013 Dec; 107(12):1904-11. PMID: 23972968; PMCID: PMC4284059.
    86. Anzueto A, Niewoehner DE, Leimer I, Rühmkorf F, Celli BR, Decramer M, Tashkin D. A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium. Respir Med. 2013 Dec; 107(12):1912-22. PMID: 23969305.
      View in: PubMed
    87. Gelb AF, Tashkin D, Make BJ, Zhong X, Garcia Gil E, Caracta C. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD. Respir Med. 2013 Dec; 107(12):1957-65. PMID: 23916502.
      View in: PubMed
    88. Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin D. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 2013 Jun; 143(6):1590-1598. PMID: 23172272; PMCID: PMC4694112.
    89. Tashkin D. Effects of marijuana smoking on the lung. Ann Am Thorac Soc. 2013 Jun; 10(3):239-47. PMID: 23802821.
      View in: PubMed
    90. Tashkin D, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013 May 08; 14:49. PMID: 23651244; PMCID: PMC3651866.
    91. Park HY, Man SF, Tashkin D, Wise RA, Connett JE, Anthonisen NA, Sin DD. The relation of serum myeloperoxidase to disease progression and mortality in patients with chronic obstructive pulmonary disease (COPD). PLoS One. 2013; 8(4):e61315. PMID: 23637811; PMCID: PMC3630209.
    92. Sharafkhaneh A, Wolf RA, Goodnight S, Hanania NA, Make BJ, Tashkin D. Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives. COPD. 2013 Aug; 10(4):482-92. PMID: 23875742.
      View in: PubMed
    93. Tashkin D. Variations in FEV1 decline over time in chronic obstructive pulmonary disease and its implications. Curr Opin Pulm Med. 2013 Mar; 19(2):116-24. PMID: 23287286.
      View in: PubMed
    94. Tashkin D. Future of fixed-dose longacting ß2-agonist and antimuscarinic combination therapy in COPD. Lancet Respir Med. 2013 Mar; 1(1):6-7. PMID: 24321790.
      View in: PubMed
    95. Yoon HI, Li Y, Man SFP, Tashkin D, Wise RA, Connett JE, Anthonisen NA, Churg A, Wright JL, Sin DD. The complex relationship of serum adiponectin to COPD outcomes COPD and adiponectin. Chest. 2012 Oct; 142(4):893-899. PMID: 22207678.
      View in: PubMed
    96. Halpin DM, Decramer M, Celli B, Kesten S, Liu D, Tashkin D. Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis. 2012; 7:653-61. PMID: 23055714; PMCID: PMC3459660.
    97. Tashkin D, Rabinoff M, Noble EP, Ritchie TL, Simmons MS, Connett J. Association of dopamine-related gene alleles, smoking behavior and decline in FEV1 in subjects with COPD: findings from the lung health study. COPD. 2012 Dec; 9(6):620-8. PMID: 22958175.
      View in: PubMed
    98. Theodore AC, Tseng CH, Li N, Elashoff RM, Tashkin D. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. Chest. 2012 Sep; 142(3):614-621. PMID: 22156609; PMCID: PMC3435135.
    99. Tashkin D, Wang HJ, Halpin D, Kleerup EC, Connett J, Li N, Elashoff R. Comparison of the variability of the annual rates of change in FEV1 determined from serial measurements of the pre- versus post-bronchodilator FEV1 over 5 years in mild to moderate COPD: results of the lung health study. Respir Res. 2012 Aug 15; 13:70. PMID: 22894725; PMCID: PMC3439318.
    100. Celli BR, Decramer M, Lystig T, Kesten S, Tashkin D. Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respir Res. 2012 Aug 06; 13:66. PMID: 22866681; PMCID: PMC3443002.
    101. Tashkin D. Is it asthma, COPD, or something in between, and does it matter? Respir Care. 2012 Aug; 57(8):1354-6. PMID: 22867646.
      View in: PubMed
    102. Baay-Guzman GJ, Bebenek IG, Zeidler M, Hernandez-Pando R, Vega MI, Garcia-Zepeda EA, Antonio-Andres G, Bonavida B, Riedl M, Kleerup E, Tashkin D, Hankinson O, Huerta-Yepez S. HIF-1 expression is associated with CCL2 chemokine expression in airway inflammatory cells: implications in allergic airway inflammation. Respir Res. 2012 Jul 23; 13:60. PMID: 22823210; PMCID: PMC3439306.
    103. Drummond MB, Hansel NN, Connett JE, Scanlon PD, Tashkin D, Wise RA. Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 Jun 15; 185(12):1301-6. PMID: 22561963.
      View in: PubMed
    104. Tashkin D, Simmons MS, Tseng CH. Impact of changes in regular use of marijuana and/or tobacco on chronic bronchitis. COPD. 2012 Aug; 9(4):367-74. PMID: 22497563.
      View in: PubMed
    105. Brown MS, Kim HJ, Abtin FG, Strange C, Galperin-Aizenberg M, Pais R, Da Costa IG, Ordookhani A, Chong D, Ni C, McNitt-Gray MF, Tashkin D, Goldin JG. Emphysema lung lobe volume reduction: effects on the ipsilateral and contralateral lobes. Eur Radiol. 2012 Jul; 22(7):1547-55. PMID: 22466511.
      View in: PubMed
    106. Tashkin D, Celli BR, Decramer M, Lystig T, Liu D, Kesten S. Efficacy of tiotropium in COPD patients with FEV1 = 60% participating in the UPLIFT® trial. COPD. 2012 Jun; 9(3):289-96. PMID: 22432932.
      View in: PubMed
    107. Tarleton HP, Park SL, Zhu WM, Lee YC, Hashibe M, Morgenstern H, Tashkin D, Mao JT, Cozen W, Mack TM, Zhang ZF. Body mass index change in adulthood and lung and upper aerodigestive tract cancers. Int J Cancer. 2012 Sep 15; 131(6):1407-16. PMID: 22131048; PMCID: PMC3402653.
    108. Doherty DE, Tashkin D, Kerwin E, Knorr BA, Shekar T, Banerjee S, Staudinger H. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis. 2012; 7:57-71. PMID: 22334769; PMCID: PMC3276257.
    109. Tashkin D, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Banerjee S, Staudinger H. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial. Int J Chron Obstruct Pulmon Dis. 2012; 7:43-55. PMID: 22334768; PMCID: PMC3276256.
    110. Tashkin D, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Gates D, Staudinger H. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis. 2012; 7:73-86. PMID: 22334770; PMCID: PMC3276258.
    111. Tashkin D. COPD Progression and individual rates of change in FEV1 and the BODE index. Am J Respir Crit Care Med. 2011 Nov 01; 184(9):988-90. PMID: 22045742.
      View in: PubMed
    112. Khanna D, Tseng CH, Farmani N, Steen V, Furst DE, Clements PJ, Roth MD, Goldin J, Elashoff R, Seibold JR, Saggar R, Tashkin D. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum. 2011 Oct; 63(10):3078-85. PMID: 21618205; PMCID: PMC3183128.
    113. Kesten S, Celli B, Decramer M, Liu D, Tashkin D. Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial. Respir Res. 2011 Sep 28; 12:129. PMID: 21955733; PMCID: PMC3190346.
    114. Tashkin D. ß-blockers associated with reduced all-cause mortality in COPD. Evid Based Med. 2012 Feb; 17(1):31-2. PMID: 21949256.
      View in: PubMed
    115. Kim HJ, Brown MS, Elashoff R, Li G, Gjertson DW, Lynch DA, Strollo DC, Kleerup E, Chong D, Shah SK, Ahmad S, Abtin F, Tashkin D, Goldin JG. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol. 2011 Dec; 21(12):2455-65. PMID: 21927793.
      View in: PubMed
    116. Roth MD, Tseng CH, Clements PJ, Furst DE, Tashkin D, Goldin JG, Khanna D, Kleerup EC, Li N, Elashoff D, Elashoff RM. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum. 2011 Sep; 63(9):2797-808. PMID: 21547897; PMCID: PMC3910296.
    117. Fukuchi Y, Fernandez L, Kuo HP, Mahayiddin A, Celli B, Decramer M, Kesten S, Liu D, Tashkin D. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology. 2011 Jul; 16(5):825-35. PMID: 21539680.
      View in: PubMed
    118. Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang ZF, Rao JY, Tashkin D, Goodglick L, Holmes EC, Cameron RB, Dubinett SM, Elashoff R, Szabo E, Elashoff D. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila). 2011 Jul; 4(7):984-93. PMID: 21733822; PMCID: PMC3153413.
    119. Halpin DM, Decramer M, Celli B, Kesten S, Leimer I, Tashkin D. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial. Lung. 2011 Aug; 189(4):261-8. PMID: 21678045; PMCID: PMC3140935.
    120. Hill J, Heslop C, Man SF, Frohlich J, Connett JE, Anthonisen NR, Wise RA, Tashkin D, Sin DD. Circulating surfactant protein-D and the risk of cardiovascular morbidity and mortality. Eur Heart J. 2011 Aug; 32(15):1918-25. PMID: 21653561.
      View in: PubMed
    121. Cooper CB, Anzueto A, Decramer M, Celli B, Tashkin D, Leimer I, Kesten S. Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials. Int J Chron Obstruct Pulmon Dis. 2011; 6:269-75. PMID: 21845038; PMCID: PMC3152465.
    122. Decramer M, Molenberghs G, Liu D, Celli B, Kesten S, Lystig T, Tashkin D. Premature discontinuation during the UPLIFT study. Respir Med. 2011 Oct; 105(10):1523-30. PMID: 21530213.
      View in: PubMed
    123. Furst DE, Tseng CH, Clements PJ, Strange C, Tashkin D, Roth MD, Khanna D, Li N, Elashoff R, Schraufnagel DE. Adverse events during the Scleroderma Lung Study. Am J Med. 2011 May; 124(5):459-67. PMID: 21531236.
      View in: PubMed
    124. Celli BR, Tashkin D, Rennard SI, McElhattan J, Martin UJ. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respir Med. 2011 Aug; 105(8):1176-88. PMID: 21531124.
      View in: PubMed
    125. Hanania NA, Sharafkhaneh A, Celli B, Decramer M, Lystig T, Kesten S, Tashkin D. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res. 2011 Jan 11; 12:6. PMID: 21219660; PMCID: PMC3027109.
    126. Sin DD, Miller BE, Duvoix A, Man SF, Zhang X, Silverman EK, Connett JE, Anthonisen NA, Wise RA, Tashkin D, Celli BR, Edwards LD, Locantore N, Macnee W, Tal-Singer R, Lomas DA. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011 May 01; 183(9):1187-92. PMID: 21216880; PMCID: PMC3114051.
    127. Au K, Mayes MD, Maranian P, Clements PJ, Khanna D, Steen VD, Tashkin D, Roth MD, Elashoff R, Furst DE. Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. Arthritis Care Res (Hoboken). 2010 Dec; 62(12):1772-8. PMID: 20740615; PMCID: PMC2994974.
    128. Tashkin D. Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD. Expert Rev Respir Med. 2010 Dec; 4(6):703-14. PMID: 21128746.
      View in: PubMed
    129. Oh SS, Chang SC, Cai L, Cordon-Cardo C, Ding BG, Greenland S, He N, Jiang Q, Kheifets L, Le A, Lee YC, Liu S, Lu ML, Mao JT, Morgenstern H, Mu LN, Pantuck A, Papp JC, Park SL, Rao JY, Reuter VE, Tashkin D, Wang H, You NC, Yu SZ, Zhao JK, Belldegrun A, Zhang ZF. Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers. Int J Cancer. 2010 Nov 01; 127(9):2169-82. PMID: 20112337; PMCID: PMC2932751.
    130. Tashkin D, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010 Oct 29; 11:149. PMID: 21034447; PMCID: PMC2991288.
    131. Tashkin D, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest. 2011 Mar; 139(3):591-599. PMID: 20864613.
      View in: PubMed
    132. Tashkin D. Frequent exacerbations of chronic obstructive pulmonary disease--a distinct phenotype? N Engl J Med. 2010 Sep 16; 363(12):1183-4. PMID: 20843256.
      View in: PubMed
    133. Copersino ML, Boyd SJ, Tashkin D, Huestis MA, Heishman SJ, Dermand JC, Simmons MS, Gorelick DA. Sociodemographic characteristics of cannabis smokers and the experience of cannabis withdrawal. Am J Drug Alcohol Abuse. 2010 Nov; 36(6):311-9. PMID: 20678028; PMCID: PMC3197209.
    134. Tashkin D. Indacaterol maleate for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2010 Aug; 11(12):2077-85. PMID: 20642373.
      View in: PubMed
    135. Tashkin D, Varghese ST. Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender. Pulm Pharmacol Ther. 2011 Feb; 24(1):147-52. PMID: 20659577.
      View in: PubMed
    136. Khanna D, Brown KK, Clements PJ, Elashoff R, Furst DE, Goldin J, Seibold JR, Silver RM, Tashkin D, Wells AU. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. Clin Exp Rheumatol. 2010 Mar-Apr; 28(2 Suppl 58):S55-62. PMID: 20576216.
      View in: PubMed
    137. Zeidler M, Corren J, Tashkin D. Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma. Curr Med Res Opin. 2010 Jun; 26(6):1295-305. PMID: 20370376.
      View in: PubMed
    138. Tashkin D. Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial. Expert Rev Respir Med. 2010 Jun; 4(3):279-89. PMID: 20524910.
      View in: PubMed
    139. Park SL, Bastani D, Goldstein BY, Chang SC, Cozen W, Cai L, Cordon-Cardo C, Ding B, Greenland S, He N, Hussain SK, Jiang Q, Lee YC, Liu S, Lu ML, Mack TM, Mao JT, Morgenstern H, Mu LN, Oh SS, Pantuck A, Papp JC, Rao J, Reuter VE, Tashkin D, Wang H, You NC, Yu SZ, Zhao JK, Zhang ZF. Associations between NBS1 polymorphisms, haplotypes and smoking-related cancers. Carcinogenesis. 2010 Jul; 31(7):1264-71. PMID: 20478923; PMCID: PMC2893801.
    140. O'Connor RD, Bleecker ER, Long A, Tashkin D, Peters S, Klingman D, Gutierrez B. Subacute lack of asthma control and acute asthma exacerbation history as predictors of subsequent acute asthma exacerbations: evidence from managed care data. J Asthma. 2010 May; 47(4):422-8. PMID: 20528597.
      View in: PubMed
    141. Tashkin D, Celli B, Kesten S, Lystig T, Decramer M. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir Med. 2010 Oct; 104(10):1495-504. PMID: 20418083.
      View in: PubMed
    142. Tashkin D. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr Opin Pulm Med. 2010 Mar; 16(2):97-105. PMID: 20019615.
      View in: PubMed
    143. Tashkin D. Preventing and managing exacerbations in COPD--critical appraisal of the role of tiotropium. Int J Chron Obstruct Pulmon Dis. 2010 Feb 18; 5:41-53. PMID: 20368910; PMCID: PMC2846152.
    144. Tashkin D, Hanania NA, McGinty J, Denis-Mize K, Chaudry I. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. Adv Ther. 2009 Nov; 26(11):1024-34. PMID: 19953349.
      View in: PubMed
    145. Tashkin D, de Lange EE. Imaging of the distal airways. J Allergy Clin Immunol. 2009 Dec; 124(6 Suppl):S78-83. PMID: 19962040; PMCID: PMC2804062.
    146. Kesten S, Celli B, Decramer M, Leimer I, Tashkin D. Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis. 2009; 4:397-409. PMID: 20037679; PMCID: PMC2793068.
    147. Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, Roth MD, Clements P, Furst DE, Khanna D, Vasunilashorn S, Li G, Tashkin D. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest. 2009 Nov; 136(5):1333-1340. PMID: 19892673; PMCID: PMC2773360.
    148. Cazzola M, Tashkin D. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD. 2009 Oct; 6(5):404-15. PMID: 19863370.
      View in: PubMed
    149. Khanna D, Tseng CH, Furst DE, Clements PJ, Elashoff R, Roth M, Elashoff D, Tashkin D. Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study. Rheumatology (Oxford). 2009 Dec; 48(12):1537-40. PMID: 19776222; PMCID: PMC2777487.
    150. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin D. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009 Nov 15; 180(10):948-55. PMID: 19729663.
      View in: PubMed
    151. Sin DD, Tashkin D, Zhang X, Radner F, Sjöbring U, Thorén A, Calverley PM, Rennard SI. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet. 2009 Aug 29; 374(9691):712-9. PMID: 19716963.
      View in: PubMed
    152. Tashkin D, Celli B, Kesten S, Lystig T, Mehra S, Decramer M. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J. 2010 Feb; 35(2):287-94. PMID: 19717481.
      View in: PubMed
    153. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin D. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009 Oct 03; 374(9696):1171-8. PMID: 19716598.
      View in: PubMed
    154. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin D. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010 Jan; 137(1):20-30. PMID: 19592475.
      View in: PubMed
    155. Kye SH, Tashkin D, Roth MD, Adams B, Nie WX, Mao JT. Recruitment strategies for a lung cancer chemoprevention trial involving ex-smokers. Contemp Clin Trials. 2009 Sep; 30(5):464-72. PMID: 19508900.
      View in: PubMed
    156. Halpin DM, Tashkin D. Defining disease modification in chronic obstructive pulmonary disease. COPD. 2009 Jun; 6(3):211-25. PMID: 19811377; PMCID: PMC2699950.
    157. Tashkin D. Does smoking marijuana increase the risk of chronic obstructive pulmonary disease? CMAJ. 2009 Apr 14; 180(8):797-8. PMID: 19364782; PMCID: PMC2665954.
    158. Au K, Khanna D, Clements PJ, Furst DE, Tashkin D. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep. 2009 Apr; 11(2):111-9. PMID: 19296883.
      View in: PubMed
    159. Tashkin D, Murray RP. Smoking cessation in chronic obstructive pulmonary disease. Respir Med. 2009 Jul; 103(7):963-74. PMID: 19285850.
      View in: PubMed
    160. Hant FN, Ludwicka-Bradley A, Wang HJ, Li N, Elashoff R, Tashkin D, Silver RM. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol. 2009 Apr; 36(4):773-80. PMID: 19286849.
      View in: PubMed
    161. Tashkin D, Donohue JF, Mahler DA, Huang H, Goodwin E, Schaefer K, Hanrahan JP, Andrews WT. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med. 2009 Apr; 103(4):516-24. PMID: 19208459.
      View in: PubMed
    162. Chao C, Jacobson LP, Jenkins FJ, Tashkin D, Martínez-Maza O, Roth MD, Ng L, Margolick JB, Chmiel JS, Zhang ZF, Detels R. Recreational drug use and risk of Kaposi's sarcoma in HIV- and HHV-8-coinfected homosexual men. AIDS Res Hum Retroviruses. 2009 Feb; 25(2):149-56. PMID: 19108691; PMCID: PMC2981355.
    163. Tashkin D, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009 Feb; 6(1):17-25. PMID: 19229704.
      View in: PubMed
    164. Rennard SI, Tashkin D, McElhattan J, Goldman M, Ramachandran S, Martin UJ, Silkoff PE. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009; 69(5):549-65. PMID: 19368417; PMCID: PMC3580134.
    165. Tashkin D. The role of tiotropium in the hospital management of exacerbation of chronic obstructive pulmonary disease. Respir Care. 2008 Dec; 53(12):1657-9. PMID: 19025697.
      View in: PubMed
    166. Chao C, Jacobson LP, Tashkin D, Martínez-Maza O, Roth MD, Margolick JB, Chmiel JS, Holloway MN, Zhang ZF, Detels R. Recreational amphetamine use and risk of HIV-related non-Hodgkin lymphoma. Cancer Causes Control. 2009 Jul; 20(5):509-16. PMID: 19011979; PMCID: PMC2862618.
    167. Park SL, Chang SC, Cai L, Cordon-Cardo C, Ding BG, Greenland S, Hussain SK, Jiang Q, Liu S, Lu ML, Mao JT, Morgenstern H, Mu LN, Ng LJ, Pantuck A, Rao J, Reuter VE, Tashkin D, You NC, Yu CQ, Yu SZ, Zhao JK, Belldegrun A, Zhang ZF. Associations between variants of the 8q24 chromosome and nine smoking-related cancer sites. Cancer Epidemiol Biomarkers Prev. 2008 Nov; 17(11):3193-202. PMID: 18990762; PMCID: PMC2664075.
    168. Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008 Oct 09; 359(15):1543-54. PMID: 18836213.
      View in: PubMed
    169. Weigt SS, Abrazado M, Kleerup EC, Tashkin D, Cooper CB. Time course and degree of hyperinflation with metronome-paced tachypnea in COPD patients. COPD. 2008 Oct; 5(5):298-304. PMID: 18972278.
      View in: PubMed
    170. Dubinett SM, Aberle DR, Tashkin D, Mao JT. The partners--airflow obstruction, emphysema, and lung cancer. Am J Respir Crit Care Med. 2008 Oct 01; 178(7):665-6. PMID: 18796652.
      View in: PubMed
    171. Mao JT, Tashkin D, Tsu IH, Serio KJ. Differential modulation of leukotriene B4 synthesis and degradation in human bronchoalveolar lavage cells by lipopolysaccharide and tobacco smoke. Cancer Prev Res (Phila). 2008 Sep; 1(4):266-74. PMID: 19138970.
      View in: PubMed
    172. Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, Elashoff RM, Furst DE, Vasunilashorn S, McNitt-Gray MF, Brown MS, Roth MD, Tashkin D. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2008 Aug; 134(2):358-367. PMID: 18641099.
      View in: PubMed
    173. Cui Y, Morgenstern H, Greenland S, Tashkin D, Mao JT, Cai L, Cozen W, Mack TM, Lu QY, Zhang ZF. Dietary flavonoid intake and lung cancer--a population-based case-control study. Cancer. 2008 May 15; 112(10):2241-8. PMID: 18327817.
      View in: PubMed
    174. Khanna D, Furst DE, Clements PJ, Tashkin D, Eckman MH. Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. Med Decis Making. 2008 Nov-Dec; 28(6):926-37. PMID: 18443209.
      View in: PubMed
    175. Lee YC, Morgenstern H, Greenland S, Tashkin D, Papp J, Sinsheimer J, Cao W, Hashibe M, You NC, Mao JT, Cozen W, Mack TM, Zhang ZF. A case-control study of the association of the polymorphisms and haplotypes of DNA ligase I with lung and upper-aerodigestive-tract cancers. Int J Cancer. 2008 Apr 01; 122(7):1630-8. PMID: 18059021; PMCID: PMC2676936.
    176. Tashkin D, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, Kesten S. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008 Apr; 31(4):742-50. PMID: 18256071.
      View in: PubMed
    177. Tashkin D, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med. 2008 Apr; 102(4):479-87. PMID: 18258423.
      View in: PubMed
    178. Sakkour A, Wang T, Tashkin D. A 56-year-old woman with COPD and multiple pulmonary nodules. Chest. 2008 Feb; 133(2):566-9. PMID: 18252924.
      View in: PubMed
    179. Chao C, Jacobson LP, Tashkin D, Martínez-Maza O, Roth MD, Margolick JB, Chmiel JS, Rinaldo C, Zhang ZF, Detels R. Recreational drug use and T lymphocyte subpopulations in HIV-uninfected and HIV-infected men. Drug Alcohol Depend. 2008 Apr 01; 94(1-3):165-71. PMID: 18180115; PMCID: PMC2691391.
    180. Tashkin D, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008; 68(14):1975-2000. PMID: 18778120.
      View in: PubMed
    181. Tashkin D. Oral vs IV corticosteroids for in-hospital treatment of COPD exacerbations. Chest. 2007 Dec; 132(6):1728-9. PMID: 18079214.
      View in: PubMed
    182. Bailey WC, Tashkin D. Pharmacologic therapy: novel approaches for chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007 Oct 01; 4(7):543-8. PMID: 17878467.
      View in: PubMed
    183. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R, Smith EA, Furst DE, Tashkin D. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008 Jan 01; 177(1):91-8. PMID: 17901414; PMCID: PMC2176114.
    184. Tashkin D, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Khanna D, Li N, Li G. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007 Nov 15; 176(10):1026-34. PMID: 17717203; PMCID: PMC2078679.
    185. Wise RA, Tashkin D. Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies. Am J Med. 2007 Aug; 120(8 Suppl 1):S4-13. PMID: 17678942.
      View in: PubMed
    186. Wise RA, Tashkin D. Preventing chronic obstructive pulmonary disease: what is known and what needs to be done to make a difference to the patient? Am J Med. 2007 Aug; 120(8 Suppl 1):S14-22. PMID: 17678939.
      View in: PubMed
    187. Harber P, Tashkin D, Simmons M, Crawford L, Hnizdo E, Connett J. Effect of occupational exposures on decline of lung function in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007 Nov 15; 176(10):994-1000. PMID: 17626912; PMCID: PMC2078677.
    188. Clements PJ, Roth MD, Elashoff R, Tashkin D, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagel D, Simms RW, Bolster M, Wise RA, Steen V, Mayes MD, Connelly K, Metersky M, Furst DE. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007 Dec; 66(12):1641-7. PMID: 17485423; PMCID: PMC2095310.
    189. Tashkin D, Klein GL, Colman SS, Zayed H, Schonfeld WH. Comparing COPD treatment: nebulizer, metered dose inhaler, and concomitant therapy. Am J Med. 2007 May; 120(5):435-41. PMID: 17466655.
      View in: PubMed
    190. Khanna D, Yan X, Tashkin D, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum. 2007 May; 56(5):1676-84. PMID: 17469162.
      View in: PubMed
    191. Murray RP, Connett JE, Skeans MA, Tashkin D. Menthol cigarettes and health risks in Lung Health Study data. Nicotine Tob Res. 2007 Jan; 9(1):101-7. PMID: 17365741.
      View in: PubMed
    192. Tashkin D. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding. Am J Med. 2006 Oct; 119(10 Suppl 1):63-72. PMID: 16996901.
      View in: PubMed
    193. Tashkin D. The role of patient-centered outcomes in defining the clinical course of chronic obstructive pulmonary disease. Introduction. Am J Med. 2006 Oct; 119(10 Suppl 1):1-3. PMID: 16996893.
      View in: PubMed
    194. Hashibe M, Morgenstern H, Cui Y, Tashkin D, Zhang ZF, Cozen W, Mack TM, Greenland S. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2006 Oct; 15(10):1829-34. PMID: 17035389.
      View in: PubMed
    195. Rutten-van Mölken MP, Oostenbrink JB, Tashkin D, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest. 2006 Oct; 130(4):1117-28. PMID: 17035446.
      View in: PubMed
    196. Zeidler MR, Goldin JG, Kleerup EC, Kim HJ, Truong DA, Gjertson DW, Kennedy NJ, Newman KB, Tashkin D, Silverman JM, Corren J. Small airways response to naturalistic cat allergen exposure in subjects with asthma. J Allergy Clin Immunol. 2006 Nov; 118(5):1075-81. PMID: 17088132.
      View in: PubMed
    197. Cole JC, Khanna D, Clements PJ, Seibold JR, Tashkin D, Paulus HE, Irwin MR, Motivala SJ, Furst DE. Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Qual Life Res. 2006 Oct; 15(8):1383-94. PMID: 16826439.
      View in: PubMed
    198. Copersino ML, Boyd SJ, Tashkin D, Huestis MA, Heishman SJ, Dermand JC, Simmons MS, Gorelick DA. Quitting among non-treatment-seeking marijuana users: reasons and changes in other substance use. Am J Addict. 2006 Jul-Aug; 15(4):297-302. PMID: 16867925.
      View in: PubMed
    199. Tashkin D, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22; 354(25):2655-66. PMID: 16790698.
      View in: PubMed
    200. Jarjour NN, Wilson SJ, Koenig SM, Laviolette M, Moore WC, Davis WB, Doherty DE, Hamid Q, Israel E, Kavuru MS, Ramsdell JW, Tashkin D, Reilly DS, Yancey SW, Edwards LD, Stauffer JL, Dorinsky PM, Djukanovic R. Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol. J Allergy Clin Immunol. 2006 Jul; 118(1):44-52. PMID: 16815137.
      View in: PubMed
    201. Fligiel SE, Standiford T, Fligiel HM, Tashkin D, Strieter RM, Warner RL, Johnson KJ, Varani J. Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury. Hum Pathol. 2006 Apr; 37(4):422-30. PMID: 16564916.
      View in: PubMed
    202. Cui Y, Morgenstern H, Greenland S, Tashkin D, Mao J, Cao W, Cozen W, Mack TM, Zhang ZF. Polymorphism of Xeroderma Pigmentosum group G and the risk of lung cancer and squamous cell carcinomas of the oropharynx, larynx and esophagus. Int J Cancer. 2006 Feb 01; 118(3):714-20. PMID: 16094634.
      View in: PubMed
    203. Sarafian TA, Habib N, Oldham M, Seeram N, Lee RP, Lin L, Tashkin D, Roth MD. Inhaled marijuana smoke disrupts mitochondrial energetics in pulmonary epithelial cells in vivo. Am J Physiol Lung Cell Mol Physiol. 2006 Jun; 290(6):L1202-9. PMID: 16414979.
      View in: PubMed
    204. Mao JT, Fishbein MC, Adams B, Roth MD, Goodglick L, Hong L, Burdick M, Strieter ER, Holmes C, Tashkin D, Dubinett SM. Celecoxib decreases Ki-67 proliferative index in active smokers. Clin Cancer Res. 2006 Jan 01; 12(1):314-20. PMID: 16397057.
      View in: PubMed
    205. Copersino ML, Boyd SJ, Tashkin D, Huestis MA, Heishman SJ, Dermand JC, Simmons MS, Gorelick DA. Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict. 2006 Jan-Feb; 15(1):8-14. PMID: 16449088.
      View in: PubMed
    206. Roth MD, Whittaker KM, Choi R, Tashkin D, Baldwin GC. Cocaine and sigma-1 receptors modulate HIV infection, chemokine receptors, and the HPA axis in the huPBL-SCID model. J Leukoc Biol. 2005 Dec; 78(6):1198-203. PMID: 16204638.
      View in: PubMed
    207. Roth MD, Tashkin D, Whittaker KM, Choi R, Baldwin GC. Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse. Life Sci. 2005 Aug 19; 77(14):1711-22. PMID: 15964028.
      View in: PubMed
    208. Tashkin D. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis. 2005 Jun; 63(2):93-100. PMID: 16128224.
      View in: PubMed
    209. Sarafian T, Habib N, Mao JT, Tsu IH, Yamamoto ML, Hsu E, Tashkin D, Roth MD. Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14; 158(2):95-107. PMID: 16039398.
      View in: PubMed
    210. Hashibe M, Straif K, Tashkin D, Morgenstern H, Greenland S, Zhang ZF. Epidemiologic review of marijuana use and cancer risk. Alcohol. 2005 Apr; 35(3):265-75. PMID: 16054989.
      View in: PubMed
    211. Tashkin D. Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease? Curr Opin Pulm Med. 2005 Mar; 11(2):121-8. PMID: 15699783.
      View in: PubMed
    212. Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG, Chung J, FitzGerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, Mayes MD, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J, Tashkin D. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum. 2005 Feb; 52(2):592-600. PMID: 15692967.
      View in: PubMed
    213. Boyd SJ, Tashkin D, Huestis MA, Heishman SJ, Dermand JC, Simmons MS, Gorelick DA. Strategies for quitting among non-treatment-seeking marijuana smokers. Am J Addict. 2005 Jan-Feb; 14(1):35-42. PMID: 15804875.
      View in: PubMed
    214. Tashkin D, Murray HE, Skeans M, Murray RP. Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II. Chest. 2004 10; 126(4):1123-33. PMID: 15486373.
      View in: PubMed
    215. Scanlon PD, Connett JE, Wise RA, Tashkin D, Madhok T, Skeans M, Carpenter PC, Bailey WC, Buist AS, Eichenhorn M, Kanner RE, Weinmann G. Loss of bone density with inhaled triamcinolone in Lung Health Study II. Am J Respir Crit Care Med. 2004 Dec 15; 170(12):1302-9. PMID: 15374846.
      View in: PubMed
    216. Clements PJ, Goldin JG, Kleerup EC, Furst DE, Elashoff RM, Tashkin D, Roth MD. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum. 2004 Jun; 50(6):1909-17. PMID: 15188367.
      View in: PubMed
    217. Gardner B, Zhu LX, Roth MD, Tashkin D, Dubinett SM, Sharma S. Cocaine modulates cytokine and enhances tumor growth through sigma receptors. J Neuroimmunol. 2004 Feb; 147(1-2):95-8. PMID: 14741436.
      View in: PubMed
    218. Roth MD, Whittaker K, Salehi K, Tashkin D, Baldwin GC. Mechanisms for impaired effector function in alveolar macrophages from marijuana and cocaine smokers. J Neuroimmunol. 2004 Feb; 147(1-2):82-6. PMID: 14741433.
      View in: PubMed
    219. Tashkin D. Evidence implicating cocaine as a possible risk factor for HIV infection. J Neuroimmunol. 2004 Feb; 147(1-2):26-7. PMID: 14741422.
      View in: PubMed
    220. Sarna L, Evangelista L, Tashkin D, Padilla G, Holmes C, Brecht ML, Grannis F. Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small cell lung cancer. Chest. 2004 Feb; 125(2):439-45. PMID: 14769722.
      View in: PubMed
    221. Zeidler MR, Kleerup EC, Tashkin D. Exhaled nitric oxide in the assessment of asthma. Curr Opin Pulm Med. 2004 Jan; 10(1):31-6. PMID: 14749603.
      View in: PubMed
    222. Tashkin D, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest. 2004 Jan; 125(1):249-59. PMID: 14718448.
      View in: PubMed
    223. Decramer M, Celli B, Tashkin D, Pauwels RA, Burkhart D, Cassino C, Kesten S. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD. 2004; 1(2):303-12. PMID: 17136995.
      View in: PubMed
    224. Mao JT, Tashkin D, Belloni PN, Baileyhealy I, Baratelli F, Roth MD. All-trans retinoic acid modulates the balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with emphysema. Chest. 2003 Nov; 124(5):1724-32. PMID: 14605041.
      View in: PubMed
    225. Gardner B, Zhu LX, Sharma S, Tashkin D, Dubinett SM. Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB J. 2003 Nov; 17(14):2157-9. PMID: 12958151.
      View in: PubMed
    226. Wise RA, Kanner RE, Lindgren P, Connett JE, Altose MD, Enright PL, Tashkin D. The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: the Lung Health Study. Chest. 2003 Aug; 124(2):449-58. PMID: 12907528.
      View in: PubMed
    227. Eichenhorn MS, Wise RA, Madhok TC, Gerald LB, Bailey WC, Tashkin D, Scanlon PD. Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. Chest. 2003 Jul; 124(1):57-62. PMID: 12853502.
      View in: PubMed
    228. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest. 2003 May; 123(5):1441-9. PMID: 12740259.
      View in: PubMed
    229. Zhu LX, Sharma S, Gardner B, Escuadro B, Atianzar K, Tashkin D, Dubinett SM. IL-10 mediates sigma 1 receptor-dependent suppression of antitumor immunity. J Immunol. 2003 Apr 01; 170(7):3585-91. PMID: 12646621.
      View in: PubMed
    230. Corren J, Tashkin D. Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma. Clin Ther. 2003 Mar; 25(3):776-98. PMID: 12852702.
      View in: PubMed
    231. Shay AH, Choi R, Whittaker K, Salehi K, Kitchen CM, Tashkin D, Roth MD, Baldwin GC. Impairment of antimicrobial activity and nitric oxide production in alveolar macrophages from smokers of marijuana and cocaine. J Infect Dis. 2003 Feb 15; 187(4):700-4. PMID: 12599091.
      View in: PubMed
    232. Berman BA, Wong GC, Bastani R, Hoang T, Jones C, Goldstein DR, Bernert JT, Hammond KS, Tashkin D, Lewis MA. Household smoking behavior and ETS exposure among children with asthma in low-income, minority households. Addict Behav. 2003 Jan-Feb; 28(1):111-28. PMID: 12507531.
      View in: PubMed
    233. Roth MD, Baldwin GC, Tashkin D. Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids. 2002 Dec 31; 121(1-2):229-39. PMID: 12505703.
      View in: PubMed
    234. Yuan M, Kiertscher SM, Cheng Q, Zoumalan R, Tashkin D, Roth MD. Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol. 2002 Dec; 133(1-2):124-31. PMID: 12446015.
      View in: PubMed
    235. Tashkin D, Baldwin GC, Sarafian T, Dubinett S, Roth MD. Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol. 2002 Nov; 42(11 Suppl):71S-81S. PMID: 12412839.
      View in: PubMed
    236. Sarafian TA, Kouyoumjian S, Khoshaghideh F, Tashkin D, Roth MD. Delta 9-tetrahydrocannabinol disrupts mitochondrial function and cell energetics. Am J Physiol Lung Cell Mol Physiol. 2003 Feb; 284(2):L298-306. PMID: 12533310.
      View in: PubMed
    237. Kleerup EC, Koyal SN, Marques-Magallanes JA, Goldman MD, Tashkin D. Chronic and acute effects of "crack" cocaine on diffusing capacity, membrane diffusion, and pulmonary capillary blood volume in the lung. Chest. 2002 Aug; 122(2):629-38. PMID: 12171843.
      View in: PubMed
    238. Sarafian TA, Kouyoumjian S, Tashkin D, Roth MD. Synergistic cytotoxicity of Delta(9)-tetrahydrocannabinol and butylated hydroxyanisole. Toxicol Lett. 2002 Jul 21; 133(2-3):171-9. PMID: 12119125.
      View in: PubMed
    239. Tashkin D. The role of small airway inflammation in asthma. Allergy Asthma Proc. 2002 Jul-Aug; 23(4):233-42. PMID: 12221892.
      View in: PubMed
    240. Sarna L, Padilla G, Holmes C, Tashkin D, Brecht ML, Evangelista L. Quality of life of long-term survivors of non-small-cell lung cancer. J Clin Oncol. 2002 Jul 01; 20(13):2920-9. PMID: 12089220.
      View in: PubMed
    241. Baldwin GC, Choi R, Roth MD, Shay AH, Kleerup EC, Simmons MS, Tashkin D. Evidence of chronic damage to the pulmonary microcirculation in habitual users of alkaloidal ("crack") cocaine. Chest. 2002 Apr; 121(4):1231-8. PMID: 11948058.
      View in: PubMed
    242. Casasola GG, Alvarez-Sala JL, Marques JA, Sánchez-Alarcos JM, Tashkin D, Espinós D. Cigarette smoking behavior and respiratory alterations during sleep in a healthy population. Sleep Breath. 2002 Mar; 6(1):19-24. PMID: 11917260.
      View in: PubMed
    243. Mao JT, Goldin JG, Dermand J, Ibrahim G, Brown MS, Emerick A, McNitt-Gray MF, Gjertson DW, Estrada F, Tashkin D, Roth MD. A pilot study of all-trans-retinoic acid for the treatment of human emphysema. Am J Respir Crit Care Med. 2002 Mar 01; 165(5):718-23. PMID: 11874821.
      View in: PubMed
    244. Roth MD, Tashkin D, Choi R, Jamieson BD, Zack JA, Baldwin GC. Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. J Infect Dis. 2002 Mar 01; 185(5):701-5. PMID: 11865430.
      View in: PubMed
    245. Gardner B, Zu LX, Sharma S, Liu Q, Makriyannis A, Tashkin D, Dubinett SM. Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta. Biochem Biophys Res Commun. 2002 Jan 11; 290(1):91-6. PMID: 11779138.
      View in: PubMed
    246. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, Gonzales D, Dozier G, Patel MK, Jamerson B. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 2001 May 19; 357(9268):1571-5. PMID: 11377644.
      View in: PubMed
    247. Tashkin D. Airway effects of marijuana, cocaine, and other inhaled illicit agents. Curr Opin Pulm Med. 2001 Mar; 7(2):43-61. PMID: 11224724.
      View in: PubMed
    248. Tashkin D. HFA-BDP and its implications for the quiet zone. Respir Med. 2000 Sep; 94 Suppl D:S37-9. PMID: 11003174.
      View in: PubMed